What is the difference between Formoterol and Albuterol (Salbutamol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Formoterol and albuterol are both essential in asthma management, but they serve different purposes: albuterol is used for quick relief of acute symptoms, while formoterol is used for long-term control and prevention of symptoms in combination with an inhaled corticosteroid. The primary distinction between these two medications lies in their onset and duration of action. Albuterol, a short-acting beta-2 agonist (SABA), acts rapidly to relieve acute symptoms and has a duration of action of 4-6 hours, making it suitable for rescue use 1. In contrast, formoterol, a long-acting beta-2 agonist (LABA), provides bronchodilation for up to 12 hours, making it more suitable for maintenance therapy rather than quick relief 1. Key points to consider in their use include:

  • Albuterol is used as needed for acute symptom relief, with a typical dosing of 2 puffs (90 mcg per puff) every 4-6 hours as needed.
  • Formoterol should always be used with an inhaled corticosteroid in asthma patients due to safety concerns associated with its use as monotherapy for long-term control of asthma, as highlighted by the Food and Drug Administration's black-box warning 1.
  • The combination of a LABA like formoterol with an inhaled corticosteroid is preferred for patients whose asthma is not adequately controlled with low-dose inhaled corticosteroids alone, as part of step 3 care or higher in guidelines for asthma management 1.
  • Patients often require both medications: albuterol for rescue and formoterol (with a corticosteroid) for daily maintenance to achieve optimal respiratory control. It's crucial to follow guidelines and recommendations from recent, high-quality studies to ensure the safe and effective use of these medications, prioritizing patient outcomes in terms of morbidity, mortality, and quality of life 1.

From the Research

Comparison of Fomoterol and Albuterol

  • Fomoterol and albuterol are both bronchodilators used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) 2, 3.
  • Albuterol is a short-acting beta 2-adrenergic receptor-selective drug that relaxes airway smooth muscle, while formoterol is a long-acting beta 2-agonist that provides improvements in spirometry measurements over 12 hours 3, 2.
  • Albuterol is currently available in oral and metered-dose inhaler forms, while formoterol is available as an inhaled medication 3, 2.

Efficacy and Safety

  • Studies have shown that albuterol is effective in treating acute bronchospasm and preventing exercise-induced bronchospasm 3, 4.
  • Formoterol has been shown to improve lung function and reduce symptoms of COPD, with a similar adverse event profile to placebo 2.
  • The use of long-acting bronchodilators like formoterol has been recommended as first-line maintenance treatment for COPD 5.

Administration and Pharmacokinetics

  • Albuterol can be administered via metered-dose inhaler or dry powder inhaler, with comparable bronchodilation effects 6.
  • Formoterol works within 5 minutes of administration and provides a prolonged duration of action due to its lipophilicity, which allows it to form a depot within the smooth muscle 2.
  • The pharmacokinetics of formoterol have been studied, with rapid absorption and excretion unchanged in the urine with a half-life of 10 hours 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease.

International journal of chronic obstructive pulmonary disease, 2020

Research

Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.